Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Myokine Expression And Tumor-Suppressive Effect Of Serum Following 12 Weeks Of Exercise In Prostate Cancer Patients On Adt, Jin-Soo Kim, Rebekah Louise Wilson, Dennis Taaffe, Daniel A. Galvao, Elin S. Gray, Robert Newton
Myokine Expression And Tumor-Suppressive Effect Of Serum Following 12 Weeks Of Exercise In Prostate Cancer Patients On Adt, Jin-Soo Kim, Rebekah Louise Wilson, Dennis Taaffe, Daniel A. Galvao, Elin S. Gray, Robert Newton
Research outputs 2014 to 2021
Purpose:
Although several mechanisms have been proposed for the tumor-suppressive effect of exercise, little attention has been given to myokines, even though skeletal muscle is heavily recruited during exercise resulting in myokine surges. We measured resting serum myokine levels before and after an exercise-based intervention and the effect of this serum on prostate cancer cell growth.
Methods:
Ten prostate cancer patients undertaking androgen deprivation therapy (age, 73.3 ± 5.6 yr) undertook a 12-wk exercise-based intervention including supervised resistance training, self-directed aerobic exercise, and protein supplementation. Body composition was assessed by dual-energy x-ray absorptiometry and muscle strength by the one-repetition maximum …
Using Exercise And Nutrition To Alter Fat And Lean Mass In Men With Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review, Rebekah L. Wilson, Dennis R. Taaffe, Robert U. Newton, Nicolas H. Hart, Philippa Lyons-Wall, Daniel A. Galvao
Using Exercise And Nutrition To Alter Fat And Lean Mass In Men With Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review, Rebekah L. Wilson, Dennis R. Taaffe, Robert U. Newton, Nicolas H. Hart, Philippa Lyons-Wall, Daniel A. Galvao
Research outputs 2014 to 2021
Fat mass (FM) gain and lean mass (LM) loss are common side effects for patients with prostate cancer receiving androgen deprivation therapy (ADT). Excess FM has been associated with an increased risk of developing obesity-related comorbidities, exacerbating prostate cancer progression, and all-cause and cancer-specific mortality. LM is the predominant contributor to resting metabolic rate, with any loss impacting long-term weight management as well as physical function. Therefore, reducing FM and preserving LM may improve patient-reported outcomes, risk of disease progression, and ameliorate comorbidity development. In ADT-treated patients, exercise and nutrition programs can lead to improvements in quality of life and …